The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical...Medico-Legal
Pharmaceuticals company Gilead is set to lose intellectual property rights for a drug it developed to treat HIV, freeing other drugs companies to launch generic...
June 13th, 2018The newer high-sensitivity troponin test discovers smaller amounts of heart-specific proteins, troponins, than the older troponin test and thus identifies more...
An affordable hepatitis C treatment has been shown to be safe and effective, with very high cure rates for patients including hard-to-treat cases, in interim clinical...Weekly Roundup
A leading Aids researcher and proponent of medication-assisted therapy for addiction has been appointed to oversee the US Centres for Disease Control and Prevention,...Weekly Roundup
This has been a lively year for HIV research says an i-base report. Even though only one new drug was approved (a once-daily version of raltegravir) several key generic...Pharmacology
For a rich country that is a global hub for pharma companies, Switzerland is going to extraordinary lengths to avoid hepatitis C patients having to pay for pricey...HIV/AIDS
Patients with HIV experienced a significantly higher rate of virologic suppression after taking Gilead’s Genvoya (elivitegravir-cobicistat-emtricitabine-tenofovir...Infectious Diseases
France will provide access to hepatitis C treatment with direct-acting antivirals to everyone diagnosed with hepatitis C from September 2016, and will begin to provide...
